A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects

Completed · Phase 1/Phase 2

Conditions studied: HIV-1 Infection, HIV Infections

In brief

The purpose of the study is to find out whether an experimental autologous dendritic cell vaccine is safe, well tolerated, and whether it can strengthen the immune system's response to HIV.

Key facts

Study ID

NCT00833781

Run by

Massachusetts General Hospital

People needed

15

Starts

2009-08-01

Expected to finish

2013-12-01

Last updated by the study team

2016-03-08

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV-1 positive
• CD4+ T Cell count >200
• Undetectable HIV viral load for 6 months prior to screening
• On antiretroviral treatment for 12 months prior to screening

You may not qualify if…

• Hepatitis C positive
• Detectable HIV viral load within 6 months prior to study entry
• Females who are pregnant or nursing

Where it is running

• Infectious Disease Unit; Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.